| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/200 - 1/1000 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | VPF; VEGF; MVCD1 |
| Entrez GeneID | 7422 |
| clone | 6G5B5 |
| WB Predicted band size | 27kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human VEGFA (AA: 207-371) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3-4条关于VEGFA抗体的参考文献及其摘要概括：
---
1. **文献名称**：*VEGF and the quest for tumour angiogenesis factors*
**作者**：Ferrara, N., et al.
**摘要**：该综述总结了VEGFA在肿瘤血管生成中的核心作用，并讨论了抗VEGFA抗体(如贝伐珠单抗)通过阻断VEGF信号通路抑制肿瘤生长的机制及临床应用潜力。
2. **文献名称**：*Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy*
**作者**：Ferrara, N., et al.
**摘要**：研究详细描述了贝伐珠单抗(抗VEGFA单克隆抗体)的研发过程及其在多种癌症(如结直肠癌、肺癌)中的治疗效果，证明其通过抑制血管生成减少肿瘤血供。
3. **文献名称**：*Intravitreal anti-VEGF therapy for neovascular age-related macular degeneration: current status and future directions*
**作者**：Rosenfeld, P.J., et al.
**摘要**：探讨了抗VEGFA抗体(如雷珠单抗)在治疗湿性年龄相关性黄斑变性(AMD)中的应用，强调其通过中和VEGFA活性减少异常血管渗漏和水肿的疗效。
4. **文献名称**：*VEGF as a key mediator of angiogenesis in cancer: targeting strategies and current clinical implications*
**作者**：Ellis, L.M., et al.
**摘要**：分析了VEGFA在肿瘤微环境中的作用机制，并比较了不同抗VEGFA抗体(如贝伐珠单抗、阿柏西普)的靶向策略及临床耐药性问题。
---
以上文献均聚焦于VEGFA抗体的生物学功能、治疗机制及在不同疾病(如癌症、眼科疾病)中的应用研究。
Vascular endothelial growth factor A (VEGFA) is a critical signaling protein involved in angiogenesis (formation of new blood vessels) and vascular permeability. It binds to receptors such as VEGFR-1 and VEGFR-2. activating pathways that promote endothelial cell proliferation, migration, and survival. Dysregulated VEGFA expression is linked to pathological conditions, including cancer, diabetic retinopathy, and age-related macular degeneration (AMD), where excessive angiogenesis or vascular leakage drives disease progression.
VEGFA antibodies are therapeutic or research tools designed to neutralize VEGFA activity. Monoclonal antibodies like bevacizumab (Avastin®) and antigen-binding fragments like ranibizumab (Lucentis®) block VEGFA from interacting with its receptors, thereby inhibiting abnormal blood vessel growth. These agents are clinically used to treat cancers (by starving tumors of blood supply) and ocular diseases like neovascular AMD (by reducing retinal edema and hemorrhage). Additionally, VEGFA antibodies serve as detection tools in immunohistochemistry or ELISA to study VEGFA expression in tissues or biological fluids.
Despite their efficacy, challenges such as drug resistance, systemic side effects (e.g., hypertension), and high treatment costs persist. Ongoing research focuses on optimizing antibody delivery, developing bispecific antibodies, and exploring combination therapies to enhance therapeutic outcomes. VEGFA remains a pivotal target in anti-angiogenic strategies, underscoring the importance of VEGFA antibodies in both clinical and experimental settings.
×
